IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis

• DOI: 10.1111/all.15647
• Publication Date: 2023-01-17T11:12:32Z
• Authors: Laura Maintz; Thomas Welchowski; Nadine Herrmann; Juliette Brauer; Claudia Traidl‐Ho...; Regina Havenith; Svenja Müller; Claudio Rhyner; Anita Dreher; ; Matthias Schmid; Thomas Bieber
• Keywords: Periostin; Endotype; Interquartile range; SCORAD; Interleukin 13

The heterogeneous (endo)phenotypes of atopic dermatitis (AD) require precision medicine. Currently, systemic therapy is recommended to patients with an Eczema Area and Severity Index (EASI)≥16. Previous studies have demonstrated improved treatment response the anti-interleukin (IL)-13 antibody tralokinumab in AD subgroups elevated levels IL-13-related biomarkers dipeptidyl-peptidase (DPP)-4 periostin.